Pilot Study of Elevated Levels of Insulin-Like Growth Factor-Binding Protein-2 as Indicators of Hepatocellular Carcinoma

Background/Aims: Insulin-like growth factor-binding protein-2 (IGFBP-2) is expressed in many malignant tissues, and elevated serum levels can be indicators of tumour activity in addition to conventional tumour markers. Our aim was to evaluate the role of IGFBP-2 levels together with insulin-like growth factor (IGF)-I, IGF-II and IGFBP-3 in the diagnostic work-up of patients with hepatocellular carcinoma (HCC). Methods: In 50 (39 males, 11 females) histologically confirmed and TNM-graded patients with HCC who had not received adjuvant chemotherapy, the basal serum levels of IGF-I, IGF-II, IGFBP-3, IGFBP-2 and α-fetoprotein (AFP) were measured. The median age of the patients was 66 (37–84) years, body mass index was normal (25 (35–16) kg/m2). Results: The levels of IGF-I, IGF-II and IGFBP-3 were diminished, as is the case when nutrition, hepatic function and growth hormone (GH) secretion are decreased. The levels of AFP and IGFBP-2 were markedly high. In 37 cases, IGFBP-2 levels were above the age-related norm, and in 40 cases AFP levels were also elevated. In 3 cases, both AFP and IGFBP-3 were normal, and in 4 cases AFP was high but IGFBP-2 normal, whereas in 10 cases AFP was normal but IGFBP-2 was high. Conclusions: In addition to AFP, IGFBP-2 appears to be a suitable marker for the evaluation of the serological status of HCC patients. A longitudinal study during disease management is required to assess the full potential of IGFBP-2 measurements as a marker.

[1]  T. Stamey,et al.  Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. , 1993, The Journal of clinical endocrinology and metabolism.

[2]  D. Clemmons,et al.  Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.

[3]  L. Bachrach,et al.  Insulin-like growth factor binding protein production in human follicular thyroid carcinoma cells. , 1995, Growth regulation.

[4]  S. J. Kim,et al.  Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. , 1999, Journal of Korean medical science.

[5]  E. Rutanen,et al.  Insulin-like growth factors and their binding proteins. , 1990, Acta endocrinologica.

[6]  Frank Duffner,et al.  In VivoExpression of Insulin-Like Growth Factor-Binding Protein-2 in Human Gliomas Increases with the Tumor Grade. , 2001, Endocrinology.

[7]  E. Baudin,et al.  Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors. , 2001, European journal of endocrinology.

[8]  C. Mantzoros,et al.  Insulin‐like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men , 2000, International journal of cancer.

[9]  Y. Higami,et al.  Insulin-like growth factor 2 and insulin-like growth factor binding protein 2 expression in hepatoblastoma. , 1995, Human pathology.

[10]  D. Trichopoulos,et al.  Hepatitis B and C viruses in the etiology of hepatocellular carcinoma; a study in Greece using third-generation assays , 2000, Cancer Causes & Control.

[11]  R. Baxter,et al.  Insulin‐like growth factor‐binding protein‐2 in patients with prostate carcinoma and benign prostatic hyperplasia , 1997, Clinical endocrinology.

[12]  B. Chiang,et al.  Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. , 1988, The Journal of laboratory and clinical medicine.

[13]  E. Kutoh,et al.  Identification and characterization of the putative retinoblastoma control element of the rat insulin-like growth factor binding protein-2 gene. , 1999, Cancer letters.

[14]  D. Lebrec,et al.  Somatomedin production in normal adults and cirrhotic patients. , 1977, Acta endocrinologica.

[15]  M. Elmlinger,et al.  Significance of Basal IGF-I, IGFBP-3 and IGFBP-2 Measurements in the Diagnostics of Short Stature in Children , 2001, Hormone Research in Paediatrics.

[16]  A. Karasik,et al.  Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. , 1996, British Journal of Cancer.

[17]  P. Schofield,et al.  Insulin-like growth factor (IGF)-I, -II and IGF binding protein-2 (IGFBP-2) in the plasma of children with Wilms' tumour. , 1993, European journal of cancer.

[18]  D. Leroith,et al.  Insulin-like Growth Factors in Health and Disease , 1992 .

[19]  J. Thrasher,et al.  Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. , 1996, The Journal of clinical endocrinology and metabolism.

[20]  W. Blum,et al.  Serum levels of insulin-like growth factor-I,-II and insulin-like growth factor binding proteins-2 and-3 in children with acute lymphoblastic leukaemia , 1996, European Journal of Pediatrics.

[21]  F. Garrouste,et al.  Alterations in serum levels of insulin‐like growth factors and insulin‐like growth‐factor‐binding proteins in patients with colorectal cancer , 1994, International journal of cancer.

[22]  J. Kratzsch,et al.  Regulation of growth hormone (GH), insulin-like growth factor (IGF)I, IGF binding proteins -1, -2, -3 and GH binding protein during progression of liver cirrhosis. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[23]  A. Hochberg,et al.  H19 in normal development and neoplasia , 1997, Molecular reproduction and development.

[24]  M. Czech,et al.  Purification and amino-terminal sequence of an insulin-like growth factor-binding protein secreted by rat liver BRL-3A cells. , 1986, The Journal of biological chemistry.

[25]  T. Pietsch,et al.  Altered expression of members of the IGF-axis in hepatoblastomas , 2000, British Journal of Cancer.

[26]  C. Trautwein,et al.  Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. , 1997, Cancer research.

[27]  Chou Ck,et al.  Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. , 1988 .

[28]  J. Holly,et al.  Growth hormone, insulinlike growth factor‐1, and insulinlike growth factor binding proteins 1 and 3 in chronic liver disease , 1995, Hepatology.

[29]  D. Clemmons,et al.  Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. , 1991, The Journal of clinical endocrinology and metabolism.

[30]  D. Peehl,et al.  The IGF axis in the prostate. , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[31]  R. Holt,et al.  The insulin-like growth factor and binding protein axis in children with end-stage liver disease before and after orthotopic liver transplantation. , 1998, Pediatric transplantation.

[32]  J. G. Reeve,et al.  Insulin‐like growth‐factor‐binding protein gene expression and protein production by human tumour cell lines , 1992, International journal of cancer.

[33]  S. Mohan,et al.  Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. , 1997, Endocrine reviews.

[34]  C. Bréchot,et al.  Expression of insulin-like growth factor II, alpha-fetoprotein and hepatitis B virus transcripts in human primary liver cancer. , 1991, Hepatology.

[35]  M. Ranke,et al.  Clinical studies of IGFBP-2 by radioimmunoassay. , 1993, Growth regulation.

[36]  M. Pinzani,et al.  Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: evidence of an altered circadian rhythm. , 1993, The American journal of gastroenterology.

[37]  M. Elmlinger,et al.  Insulin-like growth factor binding protein 2 is differentially expressed in leukaemic B- and T-cell lines. , 1996, Growth regulation.

[38]  W. Blum,et al.  Elevated serum levels of IGFBP-2 found in children suffering from acute leukaemia is accompanied by the occurrence of IGFBP-2 mRNA in the tumour clone. , 1998, British Journal of Cancer.

[39]  A. Karasik,et al.  Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. , 1994, The Journal of clinical endocrinology and metabolism.

[40]  Hiromu Suzuki,et al.  Allelic-expression imbalance of the insulin-like growth factor 2 gene in hepatocellular carcinoma and underlying disease. , 1996, Oncogene.

[41]  S. Finkelstein,et al.  Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Pollak,et al.  Circulating IGF-I: New Perspectives for a New Century , 1999, Trends in Endocrinology & Metabolism.

[43]  M. Elmlinger,et al.  In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. , 2001, Endocrinology.

[44]  D. Sens,et al.  Expression of insulin-like growth factor binding protein 2 (IGFBP-2) in Wilms' tumors. , 1994, Pediatric pathology.

[45]  K. Havemann,et al.  Production of insulin-like growth factor binding proteins by human ovarian carcinoma cells , 2005, Journal of Cancer Research and Clinical Oncology.

[46]  S. Corroyer,et al.  Expression of insulin-like growth factors and their binding proteins by bronchoalveolar cells from children with and without interstitial lung disease. , 1998, The European respiratory journal.

[47]  W. Blum,et al.  Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. , 1994, The Journal of clinical endocrinology and metabolism.

[48]  C. Bréchot,et al.  Expression of insulin‐like growth factor II, α‐fetoprotein and hepatitis B virus transcripts in human primary liver cancer , 1991 .

[49]  Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. , 1997, The Journal of clinical endocrinology and metabolism.